IRCT201103171414N23
Completed
Phase 2
Investigation on autologous mesenchymal stem cell transplantation in diabetic neurophaty
???Endocrinology & Metabolism Research Institute Tehran University Of Medical Sciences0 sites20 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Diabetic neurophaty.
- Sponsor
- ???Endocrinology & Metabolism Research Institute Tehran University Of Medical Sciences
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\-People with diabetes type one that their disease passed at least 10 years 2\-signing informed consent, 3\-age 40\-60 years4\- All patients are eligible for cell therapy (under protocol) 5 \- HbA1c \= 7\.5% (blood glucose is controlled at least of one month) 6 \- BP \= 130/80Exclusion criteria: 1 \- acute inflammation of vascular 2 \- acute thrombosis (three months) 3 \- recent bleeding in the retina (the last three months) 4 \- pulmonary hypertension 5 \- liver disease 6\- tumors in bone marrow or any malignancy is diagnosed 7 \- infectious diseases 8\-mental illness 9\- generalized edema 10 \- malignancy 11 \- pregnancy 12 \- to use any walking aids 13 \- having a foot ulcer during the study 14 \- amputation of limbs
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Early Phase 1
Investigation on autologous mesenchymal stem cell transplantation in diabetic retinopathydiabetic retinopathy (dibetes type one).Diabetic retinopathyH36.0*IRCT201111291414N29The EMRI Endocrinology and Metabolism Research Institute ? Tehran University of Medical Sciences20
Completed
Early Phase 1
Investigation on autologous mesenchymal stem cell transplantation in diabetic nephrophaty (type one)Diabetes Nephropathy (type 1).Glomerular disorders in diabetes mellitusIRCT201111291414N28Endocrinology and Metabolism Research Institute (EMRI)20
Active, not recruiting
Phase 1
SMART-MSMultiple sclerosisMedDRA version: 20.1Level: PTClassification code: 10028245Term: Multiple sclerosis Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]CTIS2023-510228-63-00Helse Bergen HF18
Not yet recruiting
Phase 2
SMART-MS2023-510228-63-00Helse Bergen HF18
Completed
Not Applicable
Mesenchymal stem cell transplantation in the treatment of type 1 diabetic patientsType 1 diabetes.Insulin-dependent diabetes mellitusIRCT138810271414N8Endocrinology & Metabolism Research Center20